A cure for migraines? New drug gets EU approval
NHS to consider offering preventative injections which cut migraine rate by half

The first licensed drug proven to be effective in preventing migraines may soon be available in the UK, after EU regulators gave it the green light.
The European Medicines Agency has approved Erenumab, specifically designed to prevent the onset of migraines, opening the door for the treatment to be made available on the NHS.
“Even were it turned down by public health officials, the manufacturer Novartis has said that patients would be able to access the medicine privately from September,” Sky News reports. The drug, which can be injected by the patient at home, works by blocking a receptor in the brain which is believed to be involved in triggering migraines - “although scientists are not completely sure what causes the agonising headaches just yet”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In clinical trials, “one in four patients with chronic migraines - those experiencing symptoms 15 days or more a month - were migraine-free for more than 15 months,” The Scientist reports.
On average, Erenumab cut the number of days that volunteers experienced a migraine in a month by half.
Wendy Thomas, the chief executive of the Migraine Trust, said the decision to approve the drug for sale in the EU was “wonderful”.
“This new treatment has the potential to help many people with chronic and episodic migraine,” she said, a condition which “can literally ruin lives”.
A world survey of health conditions across 195 countries found that, “in every year from 1990 to 2016, migraine attacks remained the second-largest global contributor to years lived with disability”, writes journalist and migraine sufferer Lauren Sharkey for the BBC.
As well as causing misery for millions, migraines also come with an economic cost. In the UK alone, the extreme headaches are responsible for around 25 million sick days taken every year.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Today's political cartoons - May 11, 2025
Cartoons Sunday's cartoons - shark-infested waters, Mother's Day, and more
-
5 fundamentally funny cartoons about the US Constitution
Cartoons Artists take on Sharpie edits, wear and tear, and more
-
In search of paradise in Thailand's western isles
The Week Recommends 'Unspoiled spots' remain, providing a fascinating insight into the past
-
Washwood Heath: Birmingham's pioneering neighbourhood health service
In the Spotlight NHS England chair says there is a 'really good argument this is the model for the future'
-
The UK's first legal drug consumption room
The Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
-
How can the UK solve the adult social care crisis?
Today's Big Question New commission announced to turn our buckling care sector around: yet more delay or finally a way forward?
-
Should blood donors be paid?
The Explainer Financial rewards would help fill NHS shortfall but bring risk of contamination and exploitation, WHO warns
-
UK gynaecological care crisis: why thousands of women are left in pain
The Explainer Waiting times have tripled over the past decade thanks to lack of prioritisation or funding for women's health
-
A 'transformative' gene therapy for haemophilia B
The Explainer Costly treatment that could be 'truly life-changing' for patients with rare blood disorder gets funding boost
-
Infected blood scandal: will justice be served?
Today's Big Question Government apologises for 'decades-long moral failure' and promises £10bn compensation but true accountability may take far longer
-
Immunotherapy and hay fever
The Explainer Research shows that the treatment could provide significant relief from symptoms for many hay fever sufferers